07.17.12
DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM N.V., has signed a biologics contract manufacturing agreement with RECEPTA Biopharma in Sao Paulo. Financial terms were not disclosed.
DSM will provide process development and cGMP manufacture of one of RECEPTA's lead antibodies at its facilities based in Groningen, The Netherlands. DSM began production to supply drug substance materials for clinical trials that began in May of 2012.
Alexander Wessels, chief executive officer of DSM Pharmaceutical Products said, "Working with RECEPTA in Brazil marks further advancement of DSM's stated strategy to grow its presence in high growth economies such as Brazil and South America. Additionally, we are committed to employ our innovative technologies to serve market needs for life-saving treatments."
Jose Fernando Perez, chief executive officer of RECEPTA Biopharma said, "This manufacturing agreement with DSM moves us one step closer to serving patient needs for this important medical treatment. We are delighted to strengthen our global network of innovation to bring our new monoclonal antibodies to the market."
DSM will provide process development and cGMP manufacture of one of RECEPTA's lead antibodies at its facilities based in Groningen, The Netherlands. DSM began production to supply drug substance materials for clinical trials that began in May of 2012.
Alexander Wessels, chief executive officer of DSM Pharmaceutical Products said, "Working with RECEPTA in Brazil marks further advancement of DSM's stated strategy to grow its presence in high growth economies such as Brazil and South America. Additionally, we are committed to employ our innovative technologies to serve market needs for life-saving treatments."
Jose Fernando Perez, chief executive officer of RECEPTA Biopharma said, "This manufacturing agreement with DSM moves us one step closer to serving patient needs for this important medical treatment. We are delighted to strengthen our global network of innovation to bring our new monoclonal antibodies to the market."